Parmodulin 2

TargetMol
Product Code: TAR-T1893
Supplier: TargetMol
CodeSizePrice
TAR-T1893-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1893-2mg2mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1893-1mL1 mL * 10 mM (in DMSO)£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1893-5mg5mg£119.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1893-10mg10mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1893-25mg25mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1893-50mg50mg£288.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1893-100mg100mg£464.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
ML 161 is the inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50: 0.26 μM for the inhibition of platelet P-selectin expression on human platelets). It also inhibits thrombin-induced platelet activation.
CAS:
423735-93-7
Formula:
C17H17BrN2O2
Molecular Weight:
361.239
Pathway:
GPCR/G Protein
Purity:
0.9995
SMILES:
CCCC(=O)Nc1cccc(NC(=O)c2ccccc2Br)c1
Target:
Protease-activated Receptor

References

1. Dockendorff C, et al. ACS Med Chem Lett, 2012, 3(3), 232-237. 2. Bing Z, Wu M, Hu Z, et al. A novel oncotherapy strategy, direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer[J]. Authorea Preprints. 2020 3. Zhao B, Wu M, Hu Z, et al. A novel oncotherapy strategy, direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non?small cell lung cancer[J]. British Journal of Pharmacology. 2021